Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Details)

v3.19.1
Segment Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2019
USD ($)
segment
Mar. 31, 2018
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 2  
Segment Reporting Information [Line Items]    
Total Revenue $ 95,577 $ 63,423
Total Cost of Revenue 48,462 36,120
GROSS PROFIT 47,115 27,303
General and administrative 32,142 17,067
Research and development 1,209 956
Sales and marketing 11,216 6,775
Total operating expenses 44,567 24,798
INCOME FROM OPERATIONS 2,548 2,505
Interest expense, net 1,826 1,486
Other expense (income) (5,169) 63
Income (loss) before taxes (4,447) 1,082
Income tax (benefit) expense (2,023) 438
NET INCOME (LOSS) (2,424) 644
Clinical Services    
Segment Reporting Information [Line Items]    
Total Revenue 86,210 56,971
Total Cost of Revenue 42,651 31,042
GROSS PROFIT 43,559 25,929
Pharma Services    
Segment Reporting Information [Line Items]    
Total Revenue 9,367 6,452
Total Cost of Revenue 5,811 5,078
GROSS PROFIT $ 3,556 $ 1,374